Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19498505 | 0.84 | TTR (0.41) | TTRENPP2KDM4EALDH1A1CA1 | |
| SCHEMBL8958922 | 0.82 | KDM4E (0.48) | TTRENPP2KDM4EALDH1A1CA1 | |
| SCHEMBL21086140 | 0.80 | — | — | |
| SCHEMBL28744374 | 0.73 | ENPP2 (0.50) | TTRENPP2KDM4EALDH1A1CA1 | |
| SCHEMBL29484231 | 0.73 | ENPP2 (0.50) | TTRENPP2KDM4EALDH1A1CA1 | |
| SCHEMBL12327206 | 0.72 | TTR (0.42) | TTRENPP2KDM4ECA1CA2 | |
| SCHEMBL13265882 | 0.72 | CASP1 (0.42) | KDM4EALDH1A1TSHR | |
| SCHEMBL28939320 | 0.70 | ENPP2 (0.46) | TTRENPP2KDM4EALDH1A1CA1 | |
| SCHEMBL3788231 | 0.70 | ALDH1A1 (0.48) | TTRENPP2KDM4EALDH1A1CA1 | |
| SCHEMBL31277787 | 0.69 | KDM4E (0.48) | TTRENPP2KDM4EALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064218-A1 | TYRO3 INHIBITORS | Halia Therapeutics, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3552607-A2 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2017-05-04 | — | — | US | disclosed |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2017-05-04 | — | — | US | disclosed |
| US-9567348-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567348-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2015-09-24 | — | — | US | disclosed |
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2015-09-24 | — | — | US | disclosed |
| US-8796270-B2 | N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor | GILEAD CONNECTICUT, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796270-B2 | N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor | GILEAD CONNECTICUT, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | TTR 2599/4885ENPP2 764/4885KDM4E 1611/4885 |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | TTR 2452/4885ENPP2 1085/4885KDM4E 1470/4885 |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | TTR 2599/4885ENPP2 764/4885KDM4E 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.